BibTex format
@article{Mazur:2018:10.1016/S1473-3099(18)30292-5,
author = {Mazur, NI and Higgins, D and Nunes, MC and Melero, JA and Langedijk, AC and Horsley, N and Buchholz, UJ and Openshaw, PJ and McLellan, JS and Englund, JA and Mejias, A and Karron, RA and Simões, EA and Knezevic, I and Ramilo, O and Piedra, PA and Chu, HY and Falsey, AR and Nair, H and Kragten-Tabatabaie, L and Greenough, A and Baraldi, E and Papadopoulos, NG and Vekemans, J and Polack, FP and Powell, M and Satav, A and Walsh, EE and Stein, RT and Graham, BS and Bont, LJ and Respiratory, Syncytial Virus Network ReSViNET Foundation},
doi = {10.1016/S1473-3099(18)30292-5},
journal = {Lancet Infectious Diseases},
pages = {e295--e311},
title = {The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates},
url = {http://dx.doi.org/10.1016/S1473-3099(18)30292-5},
volume = {18},
year = {2018}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide.
AU - Mazur,NI
AU - Higgins,D
AU - Nunes,MC
AU - Melero,JA
AU - Langedijk,AC
AU - Horsley,N
AU - Buchholz,UJ
AU - Openshaw,PJ
AU - McLellan,JS
AU - Englund,JA
AU - Mejias,A
AU - Karron,RA
AU - Simões,EA
AU - Knezevic,I
AU - Ramilo,O
AU - Piedra,PA
AU - Chu,HY
AU - Falsey,AR
AU - Nair,H
AU - Kragten-Tabatabaie,L
AU - Greenough,A
AU - Baraldi,E
AU - Papadopoulos,NG
AU - Vekemans,J
AU - Polack,FP
AU - Powell,M
AU - Satav,A
AU - Walsh,EE
AU - Stein,RT
AU - Graham,BS
AU - Bont,LJ
AU - Respiratory,Syncytial Virus Network ReSViNET Foundation
DO - 10.1016/S1473-3099(18)30292-5
EP - 311
PY - 2018///
SN - 1473-3099
SP - 295
TI - The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
T2 - Lancet Infectious Diseases
UR - http://dx.doi.org/10.1016/S1473-3099(18)30292-5
UR - https://www.ncbi.nlm.nih.gov/pubmed/29914800
UR - http://hdl.handle.net/10044/1/61037
VL - 18
ER -
